Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | AGER | Q15109 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | DHODH | Q02127 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7083112 | 0.85 | PARP1 (0.47) | KDM4ETDP1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL29900286 | 0.83 | ALDH1A1 (0.35) | KDM4ETDP1ALDH1A1L3MBTL1ALOX15 | |
| SCHEMBL17714447 | 0.81 | L3MBTL1 (0.50) | KDM4ETDP1ALDH1A1L3MBTL1ALOX15 | |
| SCHEMBL22800090 | 0.79 | KDM4E (0.44) | KDM4ETDP1ALDH1A1L3MBTL1ALOX15 | |
| SCHEMBL5252687 | 0.78 | KDM4E (0.59) | KDM4ETDP1ALDH1A1L3MBTL1ALOX15 | |
| SCHEMBL3880000 | 0.78 | KDM4E (0.59) | KDM4ETDP1ALDH1A1L3MBTL1ALOX15 | |
| SCHEMBL242926 | 0.77 | SMN1; SMN2 (0.58) | KDM4ETDP1ALDH1A1L3MBTL1ALOX15 | |
| SCHEMBL123202 | 0.77 | KDM4E (0.57) | KDM4ETDP1ALDH1A1L3MBTL1ALOX15 | |
| SCHEMBL2782918 | 0.77 | KDM4E (0.62) | KDM4ETDP1ALDH1A1L3MBTL1ALOX15 | |
| SCHEMBL14515519 | 0.77 | KDM4E (0.57) | KDM4ETDP1ALDH1A1L3MBTL1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150297761-A1 | PEPTIDIC STRUCTURES INCORPORATING AN AMINO ACID METAL COMPLEX AND APPLICATIONS IN MAGNETIC RESONANCE IMAGING | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2015-10-22 | — | — | US | claimed |
| WO-2014075079-A1 | PEPTIDIC STRUCTURES INCORPORATING AN AMINO ACID METAL COMPLEX AND APPLICATIONS IN MAGNETIC RESONANCE IMAGING | THE GENERAL HOSPITAL CORPORATION (US) | 2014-05-15 | — | — | WO | claimed |
| EP-1363886-B1 | PROCESS AND CATALYST FOR THE PREPARATION OF ACETYLPYRIDINES | LONZA AG (CH) | 2008-06-04 | — | — | EP | claimed |
| CN-108192655-B | Method for extracting and removing sulfur-containing compounds in crude oil | 中国石油大学(华东) | 2020-03-10 | — | — | CN | disclosed |
| US-20150297761-A1 | PEPTIDIC STRUCTURES INCORPORATING AN AMINO ACID METAL COMPLEX AND APPLICATIONS IN MAGNETIC RESONANCE IMAGING | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2015-10-22 | — | — | US | disclosed |
| WO-2014075079-A1 | PEPTIDIC STRUCTURES INCORPORATING AN AMINO ACID METAL COMPLEX AND APPLICATIONS IN MAGNETIC RESONANCE IMAGING | THE GENERAL HOSPITAL CORPORATION (US) | 2014-05-15 | — | — | WO | disclosed |
| US-20080287492-A1 | Alkylpyridyl Quinolines as Nk3 Receptor Modulators | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | disclosed |
| EP-1915361-A1 | ALKYLPYRIDYL QUINOLINES AS NK3 RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2008-04-30 | — | — | EP | disclosed |
| WO-2007018466-A1 | ALKYLPYRIDYL QUINOLINES AS NK3 RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | WO | disclosed |
| US-7081503-B2 | Process producing vinyl polymer having alkenyl group at end, vinyl polymer, and curable composition | KANEKA CORPORATION (JP) | 2006-07-25 | — | — | US | disclosed |
| US-7009004-B2 | Process for producing vinyl polymer having alkenyl group at end vinyl polymer and curable composition | KANEKA CORPORATION (JP) | 2006-03-07 | — | — | US | disclosed |
| US-20040097678-A1 | Process for producing vinyl polymer having alkenyl group at end vinyl polymer and curable composition | KANEKA CORPORATION (JP) | 2004-05-20 | — | — | US | disclosed |
| EP-1375531-A1 | PROCESS FOR PRODUCING VINYL POLYMER HAVING ALKENYL GROUP AT END, VINYL POLYMER, AND CURABLE COMPOSITION | KANEKA CORPORATION (JP) | 2004-01-02 | — | — | EP | disclosed |
| US-5808067-A | Process for preparing pyridine and quinoline derivatives | HOECHST CELANESE CORPORATION (US) | 1998-09-15 | — | — | US | disclosed |
| US-5405987-A | N-hydroxyaspartic acid derivatives; chemical intermediates | HOECHST CELANESE CORPORATION (US) | 1995-04-11 | — | — | US | disclosed |
| US-5322948-A | Reacting unsaturated diacid or derivative with hydroxylamine or a salt thereof to form N-hydroxy-2-aminobutane diacid derivative | HOECHST CELANESE CORPORATION (US) | 1994-06-21 | — | — | US | disclosed |
| EP-0511446-A2 | Process for preparing pyridinecarboxylic acid derivatives | HOECHST CELANESE CORPORATION (US) | 1992-11-04 | — | — | EP | disclosed |
| EP-0456504-A2 | Process for preparing pyridinecarboxylic acid derivatives | HOECHST CELANESE CORPORATION (US) | 1991-11-13 | — | — | EP | disclosed |
| EP-0452094-A2 | A method of the preparation of N-hydroxy aspartic acid derivate | HOECHST CELANESE CORPORATION (US) | 1991-10-16 | — | — | EP | disclosed |
| EP-0415767-A2 | Process for preparing pyridine carboxylic acid derivatives | HOECHST CELANESE CORPORATION (US) | 1991-03-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150297761-A1 | PEPTIDIC STRUCTURES INCORPORATING AN AMINO ACID METAL COMPLEX AND APPLICATIONS IN MAGNETIC RESONANCE IMAGING | ARGLU1, CA1, SSTR3 | KDM4E 2787/4885TDP1 2691/4885ALDH1A1 4165/4885 |
| US-20080287492-A1 | Alkylpyridyl Quinolines as Nk3 Receptor Modulators | ADORA3, KCNA3, TACR1 | KDM4E 1449/4885TDP1 3968/4885ALDH1A1 2243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.